Skip to content

The efficacy of bupivacaine liposome-performed anterior serratus plane block for analgesia in patients with multiple rib fractures

The efficacy of bupivacaine liposome-performed anterior serratus plane block for analgesia in patients with multiple rib fractures

Status
Active, not recruiting
Phases
Phase 4
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2300079123
Enrollment
Unknown
Registered
2023-12-26
Start date
2024-01-01
Completion date
Unknown
Last updated
2024-01-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pain

Interventions

Bupivacaine liposome low concentration group:anterior serratus plane block by injection of 30 mL of liposomal bupivacaine (89mg)
Bupivacaine liposome medium concentration group:anterior serratus plane block by injection of 30 mL of liposomal bupivacaine (177mg)
Bupivacaine liposome high concentration group:anterior serratus plane block by injection of 30 mL of liposomal bupivacaine (266mg)
Ropivacaine group:anterior serratus plane block by injection of 30 mL of ropivacaine (75mg)
Lidocaine group:anterior serratus plane block by injection of 30 mL of lidocaine (300mg)

Sponsors

The First People's Hospital of Zhangjiagang
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 65 Years

Inclusion criteria

Inclusion criteria: a. Aged 18-65 years and gender unlimited. b. Meet the diagnostic criteria for multiple rib fractures (may need to be confirmed by imaging). c. Pain VAS score =4 points. d. No serious cardiovascular, respiratory, liver and kidney function diseases. e. Agreed to receive bupivacaine liposomes for anterior serration plane block treatment, while not receiving other analgesic drugs, and voluntarily signed the patient's informed consent.

Exclusion criteria

Exclusion criteria: a. Hypersensitivity to local anesthetics or liposomes. b. Suffering from severe cardiovascular, respiratory, liver and kidney dysfunction. c. Use of other analgesics in the 24 hours prior to treatment. d. Have obvious mental illness or cognitive impairment. e. Pregnant or lactating female patients. f. Inability to cooperate with treatment or evaluation. g. There are other factors that may have influenced the results of the study, such as alcohol and drug abuse. h. Refusal to sign informed consent.

Design outcomes

Primary

MeasureTime frame
VAS pain score ;

Secondary

MeasureTime frame
Duration of analgesia;Analgesic efficiency;Anxiety and depression scores;Spirometry;Recovery quality;Gastrointestinal motility and digestion;Post-blockade adverse reactions;Block implementation time;

Countries

China

Contacts

Public ContactXu Zhenhua

The First People's Hospital of Zhangjiagang

zhenhua_email@163.com+86 134 0255 9681

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026